Medical marijuana research comes in all shapes and sizes. Some companies are diving into the use of Cannabis to help cure fatal illnesses, while others are taking the plant and transforming it into mainstream solutions for common everyday problems.
One company that is trying to revolutionize the industry is AXIM Biotechnologies with their new creation called CanChew Plus, which is believed to treat stomach cramps, bloating and diarrhea associated with IBS.
What is IBS?
Irritable Bowel Syndrome, aka IBS, is a common gut disorder. It’s quite a common disorder that causing discomfort in the bowel. The symptoms can be quite variable and include tummy pain, bloating and sometimes bouts of diarrhea and/or constipation.
As of now, up to 20% of American adults suffer from IBS at some point in their lives. While the exact reasons as to why it occurs are still unknown, the American College of Gastroenterology, clearly defined IBS by what it is not:
- It is not an anatomical or a structural problem.
- It is not an identifiable physical or chemical disorder.
- It is not a cancer and will not cause cancer.
- It will not cause other gastrointestinal diseases.
According to Renger Witkamp, a nutrition and pharmacology professor at Wageningen University; “People often experience sudden flare-ups, and for many, it has an adverse impact on their quality of life. CBD has shown to have promising effects, but there has been a clear need for practical and effective formulations.”
Cannabidiol (CBD) comes in many forms, including oils and pills, but Witkamp believes that gum will deliver a sustained release dosage of CBD in a highly bioavailable form.
Axim also makes CanChew, a controlled-release CBD chewing gum, and a combination CBD/THC gum called MedChew Rx, which is currently undergoing clinical trials for the treatment of multiple sclerosis-related pain and spasticity.
While standard CanChew gum is already available in all 50 US states, Axim says that due to current federal laws only contains hemp-based CBD.
According to Axim CEO Anastassov, if the IBS trial is successful they will be ready to proceed immediately with further trials on their pharmaceutical grade CanChew Rx products to treat inflammatory bowel disease (IBD), ulcerative colitis, and Crohn’s disease.
Related Article: Cannabis and Depression | New Treatments for 2017